These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Evaluation of EZH2 expression, BRAF V600E mutation, and CDKN2A/B deletions in epithelioid glioblastoma and anaplastic pleomorphic xanthoastrocytoma. Wang J; Liu Z; Cui Y; Liu Y; Fang J; Xu L; He Y; Du J; Su Y; Zou W; Xu Z; Li G J Neurooncol; 2019 Aug; 144(1):137-146. PubMed ID: 31214915 [TBL] [Abstract][Full Text] [Related]
10. BRAF mutation and anaplasia may be predictive factors of progression-free survival in adult pleomorphic xanthoastrocytoma. Tabouret E; Bequet C; Denicolaï E; Barrié M; Nanni I; Metellus P; Dufour H; Chinot O; Figarella-Branger D Eur J Surg Oncol; 2015 Dec; 41(12):1685-90. PubMed ID: 26454767 [TBL] [Abstract][Full Text] [Related]
11. BRAF V600E mutations are frequent in dysembryoplastic neuroepithelial tumors and subependymal giant cell astrocytomas. Lee D; Cho YH; Kang SY; Yoon N; Sung CO; Suh YL J Surg Oncol; 2015 Mar; 111(3):359-64. PubMed ID: 25346165 [TBL] [Abstract][Full Text] [Related]
12. A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytoma. Tomić TT; Olausson J; Wilzén A; Sabel M; Truvé K; Sjögren H; Dósa S; Tisell M; Lannering B; Enlund F; Martinsson T; Åman P; Abel F PLoS One; 2017; 12(4):e0175638. PubMed ID: 28448514 [TBL] [Abstract][Full Text] [Related]
13. V600E BRAF mutation in pilocytic astrocytoma is associated with a more diffuse growth pattern but does not confer a more aggressive clinical behavior. Bannykh SI; Mirocha J; Nuno M; Lopategui J; Kandala G Clin Neuropathol; 2014; 33(6):388-98. PubMed ID: 25066317 [TBL] [Abstract][Full Text] [Related]
14. BRAF-mutated pleomorphic xanthoastrocytoma is associated with temporal location, reticulin fiber deposition and CD34 expression. Koelsche C; Sahm F; Wöhrer A; Jeibmann A; Schittenhelm J; Kohlhof P; Preusser M; Romeike B; Dohmen-Scheufler H; Hartmann C; Mittelbronn M; Becker A; von Deimling A; Capper D Brain Pathol; 2014 Apr; 24(3):221-9. PubMed ID: 24345274 [TBL] [Abstract][Full Text] [Related]
15. A novel, potentially targetable TMEM106B-BRAF fusion in pleomorphic xanthoastrocytoma. Hsiao SJ; Karajannis MA; Diolaiti D; Mansukhani MM; Bender JG; Kung AL; Garvin JH Cold Spring Harb Mol Case Stud; 2017 Mar; 3(2):a001396. PubMed ID: 28299358 [TBL] [Abstract][Full Text] [Related]
17. Identification of Huang W; Cai J; Lin N; Xu Y; Wang H; Wu Z; Kang D AJNR Am J Neuroradiol; 2021 Dec; 42(12):2152-2159. PubMed ID: 34725042 [TBL] [Abstract][Full Text] [Related]
18. Clinicopathological and genetic association between epithelioid glioblastoma and pleomorphic xanthoastrocytoma. Furuta T; Miyoshi H; Komaki S; Arakawa F; Morioka M; Ohshima K; Nakada M; Sugita Y Neuropathology; 2018 Jun; 38(3):218-227. PubMed ID: 29532523 [TBL] [Abstract][Full Text] [Related]
19. Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression. Chappé C; Padovani L; Scavarda D; Forest F; Nanni-Metellus I; Loundou A; Mercurio S; Fina F; Lena G; Colin C; Figarella-Branger D Brain Pathol; 2013 Sep; 23(5):574-83. PubMed ID: 23442159 [TBL] [Abstract][Full Text] [Related]
20. Dabrafenib in BRAFV600-mutated anaplastic pleomorphic xanthoastrocytoma. Brown NF; Carter T; Mulholland P CNS Oncol; 2017 Jan; 6(1):5-9. PubMed ID: 27781490 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]